The historical data trend for Selvita's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:787 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Selvita's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Selvita's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (FRA:787) has a Buyback Yield % of 0.00 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Selvita and its competitors. According to the industry distribution chart, Selvita ranks #999999 out of 91 companies in the Medical Diagnostics & Research industry.
Is Selvita's Buyback Yield % too high?
Selvita's current Buyback Yield % is 0.00. Based on the distribution chart, Selvita ranks #999999 out of 91 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Selvita has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Selvita's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #999999 out of 91 companies for Buyback Yield %. This places Selvita in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Selvita and its competitors. Selvita's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Selvita (FRA:787) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €13.44, compared to a current price of €6.75 — trading 49.8% below its estimated fair value. The current Buyback Yield % is 0.00. Selvita's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Selvita (FRA:787), the current Buyback Yield % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (FRA:787) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of €6.75 is trading 49.8% below its estimated GF Value™ of €13.44.
Key valuation signals for FRA:787:
Buyback Yield %: 0.00
GF Value™: €13.44 vs. price of €6.75 (49.8% below fair value)
No single metric tells the full story. See the FRA:787 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
80GF Score
Get the complete analysis for FRA:787
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:787 has been successfully added to your 
